News - Neuroendocrine Cancer UK

National Cancer Patient Experience Survey 2017

by Leanne Talbot | Aug 14, 2018

The National Cancer Patient Experience Survey has been designed to monitor national progress on cancer care; to provide information to drive local quality improvements; to assist commissioners and providers of cancer care; and to inform the work of the various...

NPF July 2018 Newsletter

by Leanne Talbot | Aug 6, 2018

Click here to read our monthly newsletter. July 2018

NET Cancer Day 2018 Awareness Campaign

by Leanne Talbot | Jul 31, 2018

**UPDATE** This campaign is now closed for future volunteers As part of our ongoing awareness programme we are looking for volunteers to help us out for NET Cancer Day 2018. This year we are reaching out to the ‘neuroendocrine doctors...

Take part in the Cancer52 Patient Survey to help influence the next Cancer Strategy

by Leanne Talbot | Jul 27, 2018

Cancer52 is currently conducting a piece of work to help inform their contribution to any new Cancer Strategy that will follow the existing one, which runs until 2020/2021. To help inform their contribution they are looking at all the issues facing people with rare...

Telotristat ethyl recommended by All Wales Medicines Strategy Group

by Leanne Talbot | Jul 27, 2018

We are pleased to share with you the news that the All Wales Medicines Strategy Group has recommend Telotristat ethyl (Xermelo®) as an option for restricted use in NHS Wales to treat carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy...

NET Patient Foundation and Royal Free Hospital publication featured in British Journal of Nursing

by Leanne Talbot | Jul 24, 2018

A publication on the prevalence of self-reported side effects in neuroendocrine tumour patients prescribed somatostatin analogues written by Catherine Bouvier (NPF’s CEO), Tara Whyand (Royal Free Hospital) and Philippa Davies (Royal Free Hospital) was recently...

National Cancer Patient Experience Survey 2017

NPF July 2018 Newsletter

NET Cancer Day 2018 Awareness Campaign

Take part in the Cancer52 Patient Survey to help influence the next Cancer Strategy

Telotristat ethyl recommended by All Wales Medicines Strategy Group

NET Patient Foundation and Royal Free Hospital publication featured in British Journal of Nursing

About Us

Subscribe

Contact

Helpline: 0800 434 6476

Office: 01926 883 487

Holly House, 74 Upper Holly Walk, Leamington Spa CV32 4JL

Email us